Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window Trial of Intratumoral Nivo800 in HNSCC
NCT07741565Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nivolumab-IRDye800CW in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Safety of nivo800 administered intratumorally at 30 days. Started Sep 2026; status: recruiting.
02
Drugs
Nivolumab-IRDye800CW
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07741565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741565.